BR112023001379A2 - Formulação de distribuição para distribuição seletiva a células imunes pulmonares, tais como macrófagos e monócitos, e método para tratar um indivíduo em necessidade da mesma - Google Patents

Formulação de distribuição para distribuição seletiva a células imunes pulmonares, tais como macrófagos e monócitos, e método para tratar um indivíduo em necessidade da mesma

Info

Publication number
BR112023001379A2
BR112023001379A2 BR112023001379A BR112023001379A BR112023001379A2 BR 112023001379 A2 BR112023001379 A2 BR 112023001379A2 BR 112023001379 A BR112023001379 A BR 112023001379A BR 112023001379 A BR112023001379 A BR 112023001379A BR 112023001379 A2 BR112023001379 A2 BR 112023001379A2
Authority
BR
Brazil
Prior art keywords
delivery
monocytes
macrophages
treatment
need
Prior art date
Application number
BR112023001379A
Other languages
English (en)
Portuguese (pt)
Inventor
Mark Saltzma W
Ntokou Aglaia
Greif Daniel
Kauffman Amy
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of BR112023001379A2 publication Critical patent/BR112023001379A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112023001379A 2020-07-28 2021-07-28 Formulação de distribuição para distribuição seletiva a células imunes pulmonares, tais como macrófagos e monócitos, e método para tratar um indivíduo em necessidade da mesma BR112023001379A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063057626P 2020-07-28 2020-07-28
US17/332,175 US20220031633A1 (en) 2020-07-28 2021-05-27 Poly(amine-co-ester) polymeric particles for selective pulmonary delivery
PCT/US2021/043514 WO2022026585A1 (en) 2020-07-28 2021-07-28 Poly(amine-co-ester) polymeric particles for selective pulmonary delivery

Publications (1)

Publication Number Publication Date
BR112023001379A2 true BR112023001379A2 (pt) 2023-02-14

Family

ID=80002419

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001379A BR112023001379A2 (pt) 2020-07-28 2021-07-28 Formulação de distribuição para distribuição seletiva a células imunes pulmonares, tais como macrófagos e monócitos, e método para tratar um indivíduo em necessidade da mesma

Country Status (10)

Country Link
US (1) US20220031633A1 (https=)
EP (1) EP4188342A1 (https=)
JP (1) JP2023536119A (https=)
KR (1) KR20230047126A (https=)
CN (1) CN116137812A (https=)
AU (1) AU2021315545A1 (https=)
BR (1) BR112023001379A2 (https=)
CA (1) CA3185957A1 (https=)
MX (1) MX2023000850A (https=)
WO (1) WO2022026585A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021293780A1 (en) 2020-06-19 2023-02-02 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
MXPA03000905A (es) 2000-08-02 2003-06-24 Slil Biomedical Corp Compuestos de poliamina ciclicos como tratamiento contra el cancer.
CA2429814C (en) 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
WO2009114614A2 (en) 2008-03-11 2009-09-17 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
US8883819B2 (en) * 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9895451B2 (en) 2011-12-02 2018-02-20 Yale University Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof
US10465042B2 (en) 2011-12-02 2019-11-05 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
US9272043B2 (en) * 2011-12-02 2016-03-01 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
WO2013082529A1 (en) 2011-12-02 2013-06-06 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
US20210189062A1 (en) 2016-03-01 2021-06-24 Alexion Pharmaceuticals, Inc. Biodegradable activated polymers for therapeutic delivery
WO2017197128A1 (en) 2016-05-11 2017-11-16 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
CA3041679A1 (en) * 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension

Also Published As

Publication number Publication date
CA3185957A1 (en) 2022-02-03
WO2022026585A1 (en) 2022-02-03
KR20230047126A (ko) 2023-04-06
EP4188342A1 (en) 2023-06-07
US20220031633A1 (en) 2022-02-03
MX2023000850A (es) 2023-02-15
AU2021315545A1 (en) 2023-02-16
JP2023536119A (ja) 2023-08-23
CN116137812A (zh) 2023-05-19

Similar Documents

Publication Publication Date Title
BR112022025855A2 (pt) Polímero, método de administração de um ou mais agentes de ácido nucleico terapêuticos, de diagnóstico ou profiláticos, ou combinações dos mesmos in vivo
Feng et al. Gel/hydrogel‐based in situ biomaterial platforms for cancer postoperative treatment and recovery
Luo et al. Tailoring hyaluronic acid hydrogels for biomedical applications
Kaur et al. Hydrogels as a potential biomaterial for multimodal therapeutic applications
Wang et al. Chiral polypeptide thermogels induce controlled inflammatory response as potential immunoadjuvants
Zhang et al. Advanced nanomedicine: redefining therapeutic paradigms for inflammatory bowel disease
Carleton et al. Methacrylic acid-based hydrogels enhance skeletal muscle regeneration after volumetric muscle loss in mice
Feng et al. XA pH-responsive and colitis-targeted nanoparticle loaded with shikonin for the oral treatment of inflammatory bowel disease in mice
Zhou et al. Harnessing nanomedicine for cartilage repair: design considerations and recent advances in biomaterials
Yu et al. Medicated wound dressings based on poly (vinyl alcohol)/poly (N‐vinyl pyrrolidone)/chitosan hydrogels
Tarawneh et al. Characterization of Chlorhexidine‐Impregnated Cellulose‐Based Hydrogel Films Intended for the Treatment of Periodontitis
Devasani et al. An overview of in situ gelling systems
Zille et al. Evaluation of intra-articular delivery of hyaluronic acid functionalized biopolymeric nanoparticles in healthy rat knees
Seib et al. Heparin-modified polyethylene glycol microparticle aggregates for focal cancer chemotherapy
Ma et al. pH‐Responsive polyglycerol nanogels for periodontitis treatment through antibacterial and pro‐angiogenesis action
Li et al. Microenvironments‐modulated biomaterials enhance spinal cord injury therapy
CN1646170A (zh) 温度响应输送系统
CN107308136A (zh) 一种载抗肿瘤药物电纺微米纤维膜及其制备方法
CN103881026B (zh) 一种聚n-乙烯基吡咯烷酮微凝胶及其制备方法和用途
Chung et al. Effects of interpenetration of thermo-sensitive gels by crosslinking of chitosan on nasal delivery of insulin: In vitro characterization and in vivo study
JP2020501646A5 (https=)
Shi et al. Applications of hydrogels and nanoparticles in the treatment of traumatic brain injury
Li et al. Nanotechnology‐mediated immunomodulation strategy for inflammation resolution
Safi et al. Chitosan-and heparin-based advanced hydrogels: their chemistry, structure and biomedical applications
BR112023001379A2 (pt) Formulação de distribuição para distribuição seletiva a células imunes pulmonares, tais como macrófagos e monócitos, e método para tratar um indivíduo em necessidade da mesma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2841 DE 17-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.